Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00690) | |||||
---|---|---|---|---|---|
Name |
Topotecan
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
topotecan; 123948-87-8; Hycamtin; Topotecan lactone; Hycamptamine; Topotecane; Topotecanum; Topotecane [INN-French]; Topotecanum [INN-Latin]; (S)-Topotecan; 9-Dimethylaminomethyl-10-hydroxycamptothecin; UNII-7M7YKX2N15; Topocecan free base; CHEMBL84; NSC609699; Hycamtin (TN); 7M7YKX2N15; Hycamtamine; CHEBI:63632; 123948-87-8 (free base); SK-S-104864-A; 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin; Hycamptin; Nogitecan; Topotecan [INN:BAN]; SKF-104864-A; SK&F-104864-A; TOPOTECANHYDROCHLORIDE; CHEMBL1607; Topophore C; Topotecan Actavis; TopoCED; Topotecan (BAN); SK&F-S-104864A; SR-01000763672; SK&F 104864 A; 9-Dimethylaminomethyl-10-hydroxycamptothecin.; CCRIS 8163; MFCD00870670; HSDB 8213; SKF-S 104864; SKF 104864; SCHEMBL3836; NCIStruc1_001659; NCIStruc2_001796; BSPBio_002348; cid_60699; GTPL7101; DTXSID3042685; EX-A834; HMS2090B20; HMS3715L03; ZINC1611274; BDBM50008935; BDBM50034026; HSCI1_000228; NSC641007; AKOS015966792; AT-2921; CCG-221171; DB01030; NSC-641007; SKF-104864; SMP2_000312; SMP2_000327; NCGC00014925-02; NCGC00014925-03; NCGC00014925-04; NCGC00014925-07; NCGC00014925-10; NCGC00014925-24; NCGC00178695-01; AC-11592; AK-72818; AS-75098; HY-13768; NCI60_004771; AB0015476; dimethylaminomethyl-ethyl-dihydroxy-[?]dione; A16815; C11158; D08618; W-1887; AB00641837-09; AB00641837-11; AB00641837-12; AB00641837-13; AB00641837-14; AB00641837_15; AB00641837_16; 948T878; Q419953; SR-01000763672-3; SR-01000763672-4; BRD-K55696337-001-03-2; BRD-K55696337-003-08-7; 123948-87-8 (net), 119413-54-6 (hydrochloride); Topotecan hydrochloride hydrate, >=98% (HPLC and enzymatic)
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Ovarian cancer | ICD-11: 2C73 | [1] | ||
PubChem CID | |||||
Formula |
C23H23N3O5
|
||||
Canonical SMILES |
CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O
|
||||
InChI |
1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
|
||||
InChIKey |
UCFGDBYHRUNTLO-QHCPKHFHSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=60700"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 421.4 | Topological Polar Surface Area | 103 | |
XlogP | 0.5 | Complexity | 867 | ||
Heavy Atom Count | 31 | Rotatable Bond Count | 3 | ||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Topotecan 0.25 mg capsule | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Glyceryl monostearate; Ferric oxide red; Titanium dioxide; Gelatin
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Glyceryl monostearate | DIG Info | Prostate cancer LNCaP cells (IC50 > 100000 nM) | [2] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Glyceryl monostearate; Titanium dioxide; Gelatin, unspecified
|
|||||
Dosage Form | Oral Capsule | |||||
Company | GlaxoSmithKline | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Glyceryl monostearate | DIG Info | Prostate cancer LNCaP cells (IC50 > 100000 nM) | [2] | |||
Topotecan 1 mg capsule | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Glyceryl monostearate; Ferric oxide red; Titanium dioxide; Gelatin
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Glyceryl monostearate | DIG Info | Prostate cancer LNCaP cells (IC50 > 100000 nM) | [2] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Glyceryl monostearate; Ferric oxide red; Titanium dioxide; Gelatin, unspecified
|
|||||
Dosage Form | Oral Capsule | |||||
Company | GlaxoSmithKline | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Glyceryl monostearate | DIG Info | Prostate cancer LNCaP cells (IC50 > 100000 nM) | [2] | |||
Topotecan Hydrochloride eq 4mg base/vial injectable | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Mannito; Tartaric Acid; Hydrochloric Acid; Sodium Hydroxide
|
|||||
Dosage Form | Injectable | |||||
Company | Fresenius Kabi Usa | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Hydrochloric acid | DIG Info | Carbonic anhydrase V (Ki = 156 nM) | [4] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Mannito; Tartaric Acid; Hydrochloric Acid
|
|||||
Dosage Form | Injectable | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Hydrochloric acid | DIG Info | Carbonic anhydrase V (Ki = 156 nM) | [4] | |||
Topotecan Hydrochloride eq 0.25mg base capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Gelatin; Glyceryl Monostearate; Hydrogenated Vegetable Oil; Titanium Dioxide; Red Iron Oxide
|
|||||
Dosage Form | Capsule | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Glyceryl monostearate | DIG Info | Prostate cancer LNCaP cells (IC50 > 100000 nM) | [2] | |||
Gelatin | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 20.5 uM) | [5] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.